FI83086B - Foerfarande foer framstaellning av komplex med tumormotverkande effekt. - Google Patents
Foerfarande foer framstaellning av komplex med tumormotverkande effekt. Download PDFInfo
- Publication number
- FI83086B FI83086B FI863599A FI863599A FI83086B FI 83086 B FI83086 B FI 83086B FI 863599 A FI863599 A FI 863599A FI 863599 A FI863599 A FI 863599A FI 83086 B FI83086 B FI 83086B
- Authority
- FI
- Finland
- Prior art keywords
- ion
- nitrate
- formula
- platinum
- trans
- Prior art date
Links
- 150000001450 anions Chemical class 0.000 claims abstract description 28
- 239000003446 ligand Substances 0.000 claims abstract description 15
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 28
- 229910002651 NO3 Inorganic materials 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 19
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 19
- -1 halide ion Chemical class 0.000 claims description 17
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 9
- 239000005977 Ethylene Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 7
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- NWAHZABTSDUXMJ-UHFFFAOYSA-N platinum(2+);dinitrate Chemical compound [Pt+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O NWAHZABTSDUXMJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052727 yttrium Inorganic materials 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 150000003057 platinum Chemical class 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004202 carbamide Substances 0.000 abstract description 2
- 125000004122 cyclic group Chemical group 0.000 abstract description 2
- SGLJYTWMWIAGEU-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N SGLJYTWMWIAGEU-UHFFFAOYSA-N 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 2
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- DHEXFVLQSQLAGQ-UHFFFAOYSA-N [Pt].NC(=O)N.C=C Chemical compound [Pt].NC(=O)N.C=C DHEXFVLQSQLAGQ-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 231100000171 higher toxicity Toxicity 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 2
- 229910000367 silver sulfate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SSJXIUAHEKJCMH-OLQVQODUSA-N (1s,2r)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-OLQVQODUSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- ONUFESLQCSAYKA-UHFFFAOYSA-N iprodione Chemical compound O=C1N(C(=O)NC(C)C)CC(=O)N1C1=CC(Cl)=CC(Cl)=C1 ONUFESLQCSAYKA-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (9)
1. Förfarande för framställning av en som läkemedel användbar förening med formeln (I): Γ 1
2 T® L1 l2 I I >l : .Pt< ixp ]n/n m HN "a L 15 [där: A avser en alkylengrupp med 2 tili 5 kolatomer; 0^—C----N avser 0-C-N eller O-ON; 20 iA och är likadana eller olika och vardera avser en neutral ligand eller en envärd eller tvävärd anjon, eller ΐΛ och är sammanlänkade och bildar en envärd anjon, en tvävärd anjon eller en grupp med formeln ; <ii): o : 25 i ✓ Cn\ HVAy (II) 30 där A och 0- --rC?—N är definierade som ovan; xp- avser en anjon med valensen g; och D Sr 0, 1, 2 eller 3], vid vilket förfarande man lAter ett platinakomplex med formeln (III): .·. 35 3i 83036 " , ΪΗ;. YT n‘ ® 5 (1 >< N'J 10 [ter; XP‘ är definierad som ovan; 2' är O, 1 eller 2; och 15 Y och Y' är likadana eller ollka och vardera avser vatten, en nitrat-jon, en hydroxijon eller en perkloratjon eller Y och Y' är sammanbundna och avser en sulfat- eller karbonatjon eller en grupp med formeln (IV): 20 u
25 H reagera med en förenlng med formeln (V): H 30 0=C<· A (V) ΊΚ . h 35 (där A är definierad som ovan). 32 83086 1 2. Förfarande enligt patentkrav 1, kännetecknat därav, att nämnda reaktion utförs i ett vattenhaltigt medium för att fram-ställa en förening där nämnda neutrala ligand ΐΛ och/eller är vatten. 5
1 Patentkrav
3. Förfarande enligt patentkrav 1, kännetecknat därav, att ΐΛ och är likadana eller olika och vardera avser vatten, en nitratjon, en halidjon, en perkloratjon, en sulfatjon, en karbonatjon, en hydroxijon, en metoxijon eller en etoxijon. 10
4. Förfarande enligt patentkrav 1, kännetecknat därav, 1 Λ att L·1- och Ir avser tillsammans en nitratjon, kloridjon, sulfatjon, hydroxijon, metoxijon, etoxijon eller nämnda grupp med formeln (II). 15
5. Förfarande enligt nägot av föregäende patentkrav, k ä n n e - t e c k n a t därav, att XP" avser en nitratjon, perkloratjon, sulfatjon eller karbonatjon.
6. Förfarande enligt patentkrav 3, kännetecknat därav, 20 att XP‘ avser en nitratjon eller en sulfatjon.
7. Förfarande enligt patentkrav 1, kännetecknat därav, att ΐΛ och L.2 avser tillsammans en hydroxijon. 25
8· Förfarande enligt patentkrav 1, kännetecknat därav, att ΐΛ och avser tillsammans nämnda grupp med formeln (II).
9. Förfarande enligt patentkrav 1, kännetecknat därav, att reagenterna och reaktionsförhällandena väljs för att framställa: 30 hydroxo(etylenkarbamid-N-O)-bisfcis-(trans-(X)-1,2-diaminocyklohexan)-: platina(II)]nitrat; hydroxo(etylenkarbamid-N,Q) -bisfcis- (trans- (d) -1,2-diaminocyklohexan) -35 platina(II)] ; 33 83086 1 hydroxo(etylenkarbamid-N-O)-bisfcis-(cis-1.2 -diarainocvklohexan) - platina(II)Jnitrat; bis(etylenkarbamid-ii-Q) -bis fcls- (trans - (J£) -1,2-diaminocyklohexan) -g platina(II)nitrat; bis(etylenkarbamid-Ji,0)-bis i cis-(trans -(d)-1,2-diaminocyklohexan)-platina(II)]nitrat; eller Ί0 hydroxo(propylenkarbamid-g,0)-bis[cis-(trans-(d)-1,2-diaminocyklo-hexan)platina(ii)]nitrat. 15 20 : 25 30 35
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19709785 | 1985-09-06 | ||
| JP19709785 | 1985-09-06 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI863599A0 FI863599A0 (fi) | 1986-09-05 |
| FI863599A FI863599A (fi) | 1987-03-07 |
| FI83086B true FI83086B (fi) | 1991-02-15 |
| FI83086C FI83086C (sv) | 1991-05-27 |
Family
ID=16368672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI863599A FI83086C (sv) | 1985-09-06 | 1986-09-05 | Förfarande för framställning av komplex med tumormotverkande effekt |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0214862B1 (sv) |
| JP (1) | JPH0655752B2 (sv) |
| KR (1) | KR890004351B1 (sv) |
| CN (1) | CN1016345B (sv) |
| AT (1) | ATE61560T1 (sv) |
| AU (1) | AU581101B2 (sv) |
| CA (1) | CA1281327C (sv) |
| DE (1) | DE3678070D1 (sv) |
| DK (1) | DK166825B1 (sv) |
| ES (1) | ES2001669A6 (sv) |
| FI (1) | FI83086C (sv) |
| HU (1) | HU196606B (sv) |
| NO (1) | NO172184C (sv) |
| PH (1) | PH25038A (sv) |
| SU (1) | SU1565347A3 (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
| FI87572C (sv) * | 1987-05-08 | 1993-01-25 | Sankyo Co | Förfarande för framställning av platinakomplex med terapeutisk effekt |
| JP3862758B2 (ja) * | 1996-03-11 | 2006-12-27 | 喜徳 喜谷 | 二核白金錯体、その調製方法及びその錯体を含有する医薬組成物 |
| ITMI991508A1 (it) * | 1999-07-09 | 2001-01-09 | Novuspharma Spa | Nitrati di bis-platino complessi con ligandi poliamminici |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207416A (en) * | 1974-09-05 | 1980-06-10 | Engelhard Minerals & Chemicals Corporation | Ethylenediamineplatinum(II) 2,4-dioxopyrimidine complexes |
| CH617587A5 (sv) * | 1974-09-05 | 1980-06-13 | Engelhard Min & Chem | |
| US4419351A (en) * | 1977-06-03 | 1983-12-06 | Research Corporation | Platinum-dioxopyrimidine complexes |
-
1986
- 1986-09-05 DK DK426486A patent/DK166825B1/da not_active IP Right Cessation
- 1986-09-05 FI FI863599A patent/FI83086C/sv not_active IP Right Cessation
- 1986-09-05 NO NO863553A patent/NO172184C/no unknown
- 1986-09-05 AU AU62415/86A patent/AU581101B2/en not_active Ceased
- 1986-09-05 JP JP61209014A patent/JPH0655752B2/ja not_active Expired - Fee Related
- 1986-09-05 SU SU864028205A patent/SU1565347A3/ru active
- 1986-09-05 HU HU863866A patent/HU196606B/hu not_active IP Right Cessation
- 1986-09-05 ES ES8601700A patent/ES2001669A6/es not_active Expired
- 1986-09-05 PH PH34223A patent/PH25038A/en unknown
- 1986-09-06 CN CN86106751A patent/CN1016345B/zh not_active Expired
- 1986-09-06 KR KR1019860007459A patent/KR890004351B1/ko not_active IP Right Cessation
- 1986-09-08 CA CA000517690A patent/CA1281327C/en not_active Expired - Fee Related
- 1986-09-08 EP EP86306914A patent/EP0214862B1/en not_active Expired - Lifetime
- 1986-09-08 AT AT86306914T patent/ATE61560T1/de not_active IP Right Cessation
- 1986-09-08 DE DE8686306914T patent/DE3678070D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK166825B1 (da) | 1993-07-19 |
| HUT41808A (en) | 1987-05-28 |
| EP0214862A2 (en) | 1987-03-18 |
| KR890004351B1 (ko) | 1989-10-31 |
| AU581101B2 (en) | 1989-02-09 |
| NO172184B (no) | 1993-03-08 |
| AU6241586A (en) | 1987-03-12 |
| HU196606B (en) | 1988-12-28 |
| FI863599A (fi) | 1987-03-07 |
| ATE61560T1 (de) | 1991-03-15 |
| CA1281327C (en) | 1991-03-12 |
| NO863553L (no) | 1987-03-09 |
| EP0214862B1 (en) | 1991-03-13 |
| JPH0655752B2 (ja) | 1994-07-27 |
| FI83086C (sv) | 1991-05-27 |
| CN1016345B (zh) | 1992-04-22 |
| ES2001669A6 (es) | 1988-06-01 |
| JPS62149692A (ja) | 1987-07-03 |
| KR870003129A (ko) | 1987-04-15 |
| NO172184C (no) | 1993-06-16 |
| SU1565347A3 (ru) | 1990-05-15 |
| EP0214862A3 (en) | 1987-12-09 |
| DK426486D0 (da) | 1986-09-05 |
| PH25038A (en) | 1991-01-28 |
| FI863599A0 (fi) | 1986-09-05 |
| NO863553D0 (no) | 1986-09-05 |
| CN86106751A (zh) | 1987-03-25 |
| DK426486A (da) | 1987-03-07 |
| DE3678070D1 (de) | 1991-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0155705B1 (en) | Antitumor platinum complexes | |
| US8980875B2 (en) | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | |
| HU184922B (en) | Process for preparing platinum/iv./-diamine complexes and pharma ceutical compositions containing thereof | |
| US4607114A (en) | Novel platinum complexes | |
| US6894049B1 (en) | Platinum complexes as antitumor agents | |
| US5318962A (en) | Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents | |
| KR900003513B1 (ko) | 유기 백금 착물 및 이를 사용한 종양 치료방법 | |
| KR910009823B1 (ko) | 백금착물(白金錯物) | |
| HU188035B (en) | Process for producing new plantinum-diamine complex | |
| US7238823B2 (en) | Platinum complexes with mononitrile-containing ligands | |
| US4687780A (en) | Anti-tumor compounds of platinum | |
| FI83086B (fi) | Foerfarande foer framstaellning av komplex med tumormotverkande effekt. | |
| EP0812852A1 (en) | Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same | |
| US4670458A (en) | Hydroxylated 1,2-diaminocyclohexane platinum complexes | |
| JPH02108693A (ja) | 白金（４）ジアミン錯体 | |
| JPS61249993A (ja) | 新規有機白金錯体及びその製法 | |
| US4880790A (en) | (Gem-heterocyclodimethanamine-N,N')platinum complexes | |
| KR910009822B1 (ko) | 백금 착화합물의 제조방법 | |
| AU4551800A (en) | Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents | |
| JPS6344591A (ja) | 白金グリ−ン錯体の製造法 | |
| CZ122994A3 (en) | Complexes of bivalent platine with amino compounds, process of their preparation and pharmaceutical compositions containing thereof | |
| JPS6230792A (ja) | 新規白金錯体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: SANKYO COMPANY LIMITED |